logo

BHST

BioHarvest Sciences·NASDAQ
--
--(--)
--
--(--)
2.09 / 10
Underperform

BioHarvest Sciences presents a mixed fundamental picture: strong revenue growth (42% YoY) and a healthy interest-coverage ratio (15.48) are offset by negative valuation metrics such as PB-ROE (4.18) and Asset-MV (-0.50). This combination leads to a 'challenging' fundamental rating with a score of 2.1/10.

Fundamental(2.09)SentimentTechnical

Analysis Checks(7/10)

Revenue-MV
Value-1.29
Score1/3
Weight10.77%
1M Return4.24%
Total operating revenue (YoY growth rate %)
Value42.05
Score2/3
Weight2.29%
1M Return1.11%
Days sales outstanding
Value22.55
Score2/3
Weight2.33%
1M Return1.10%
Profit-MV
Value0.46
Score2/3
Weight21.39%
1M Return8.45%
Net income-Revenue
Value-0.17
Score2/3
Weight21.41%
1M Return8.45%
PB-ROE
Value4.18
Score0/3
Weight6.39%
1M Return2.72%
Interest coverage ratio (EBIT / Interest expense) (%)
Value15.48
Score2/3
Weight-2.14%
1M Return-1.11%
Operating revenue (YoY growth rate %)
Value42.05
Score2/3
Weight0.88%
1M Return0.43%
Asset-MV
Value-0.50
Score1/3
Weight15.65%
1M Return6.68%
Cash-MV
Value-0.07
Score2/3
Weight21.03%
1M Return8.41%
Is BHST undervalued or overvalued?
  • BHST scores 2.09/10 on fundamentals and holds a Premium valuation at present. Backed by its -197.04% ROE, -36.33% net margin, -9.13 P/E ratio, 14.03 P/B ratio, and 41.38% earnings growth, these metrics solidify its Underperform investment rating.